Immuneering (IMRX) Common Equity (2020 - 2026)
Immuneering (IMRX) posted quarterly Common Equity of $206.5 million for Q1 2026, up 393.56% year-over-year from $41.8 million in Q1 2025, and down 5.48% quarter-over-quarter from $218.5 million in Q4 2025.
Immuneering (IMRX) Common Equity (2020 - 2026) Analysis & Trends
Immuneering's Common Equity history runs 7 years deep, the most recent figure standing at $206.5 million for Q1 2026.
- In Q1 2026, Common Equity rose 393.56% year-over-year to $206.5 million; the TTM figure through Mar 2026 stood at $206.5 million (up 393.56% YoY), while the FY2025 annual figure was $218.5 million, up 427.91% from the prior year.
- Common Equity for Q1 2026 stood at $206.5 million, down from $218.5 million in the prior quarter.
- The five-year high for Common Equity was $228.0 million in Q3 2025, with the low at $28.9 million in Q2 2025.
- The 5-year median for Common Equity is $104.0 million (2023), against an average of $110.9 million.
- The sharpest annual moves came in 2022 and 2025: Common Equity surged 604.95% in 2022, then plunged 56.36% in 2025.
- Immuneering's Common Equity stood at $109.9 million in 2022, then dropped by 17.55% to $90.6 million in 2023, then sank by 54.31% to $41.4 million in 2024, then surged by 427.91% to $218.5 million in 2025, then decreased by 5.48% to $206.5 million in 2026.
- Business Quant data shows IMRX's Common Equity at $206.5 million in Q1 2026, $218.5 million in Q4 2025, and $228.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Immuneering | 327.37 Mn | 327.37 Mn | - | 190.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 190.74 Mn |
| Mar 31, 2026 | 206.52 Mn |
| Dec 31, 2025 | 218.48 Mn |
| Sep 30, 2025 | 227.98 Mn |
| Jun 30, 2025 | 28.94 Mn |
| Mar 31, 2025 | 41.84 Mn |
| Dec 31, 2024 | 41.39 Mn |
| Sep 30, 2024 | 57.72 Mn |
| Jun 30, 2024 | 66.31 Mn |
| Mar 31, 2024 | 78.72 Mn |
| Dec 31, 2023 | 90.58 Mn |
| Sep 30, 2023 | 104.02 Mn |
| Jun 30, 2023 | 115.10 Mn |
| Mar 31, 2023 | 97.79 Mn |
| Dec 31, 2022 | 109.85 Mn |
| Sep 30, 2022 | 121.89 Mn |
| Jun 30, 2022 | 133.59 Mn |
| Mar 31, 2022 | 144.06 Mn |
| Dec 31, 2021 | 155.98 Mn |
| Sep 30, 2021 | 158.29 Mn |